Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026)
Viatris' (VTRS) quarterly Depreciation & Amortization (CF) came in at $676.1 million in Q1 2026, up 1.72% year-on-year from $664.7 million in Q1 2025, and down 11.83% quarter-over-quarter from $766.8 million in Q4 2025.
Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Viatris' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $676.1 million for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 1.72% year-over-year to $676.1 million in Q1 2026; TTM through Mar 2026 was $2.8 billion, a 2.0% decrease from a year earlier, with the FY2025 full-year figure at $2.8 billion, down 3.28% from the prior year.
- Depreciation & Amortization (CF) slipped to $676.1 million in Q1 2026 per VTRS's latest filing, from $766.8 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $869.8 million in Q4 2022 and bottomed at $644.4 million in Q4 2023.
- The 5-year median for Depreciation & Amortization (CF) is $691.0 million (2024), against an average of $713.9 million.
- Biggest YoY gain for Depreciation & Amortization (CF) was 16.0% in 2022; the steepest drop was 48.26% in 2022.
- Year by year, Depreciation & Amortization (CF) stood at $869.8 million in 2022, then slipped by 25.91% to $644.4 million in 2023, then gained by 15.8% to $746.2 million in 2024, then gained by 2.76% to $766.8 million in 2025, then retreated by 11.83% to $676.1 million in 2026.
- Per Business Quant, the three latest VTRS Depreciation & Amortization (CF) figures stand at $676.1 million (Q1 2026), $766.8 million (Q4 2025), and $688.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 676.10 Mn |
| Mar 31, 2026 | 676.10 Mn |
| Dec 31, 2025 | 766.80 Mn |
| Dec 31, 2025 | 766.80 Mn |
| Sep 30, 2025 | 688.50 Mn |
| Sep 30, 2025 | 688.50 Mn |
| Jun 30, 2025 | 678.30 Mn |
| Jun 30, 2025 | 678.30 Mn |
| Mar 31, 2025 | 664.70 Mn |
| Mar 31, 2025 | 664.70 Mn |
| Dec 31, 2024 | 746.20 Mn |
| Dec 31, 2024 | 746.20 Mn |
| Sep 30, 2024 | 669.70 Mn |
| Sep 30, 2024 | 669.70 Mn |
| Jun 30, 2024 | 786.30 Mn |
| Jun 30, 2024 | 786.30 Mn |
| Mar 31, 2024 | 691.00 Mn |
| Mar 31, 2024 | 691.00 Mn |
| Dec 31, 2023 | 644.40 Mn |
| Dec 31, 2023 | 644.40 Mn |